Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.81 USD
Change Today -0.05 / -1.30%
Volume 4.7K
ISCO On Other Exchanges
As of 2:43 PM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/22/14 - $18.15
52 Week Low
08/4/15 - $1.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

international stem cell corp (ISCO) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCO) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCO) Details

International Stem Cell Corporation, a biotechnology company, focuses on development of therapeutic and biomedical products worldwide. The company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. It develops cell types, including neural stem cells for the treatment of Parkinson’s disease and other neurological disorders; liver cells to treat various congenital and acquired liver diseases; islet cells for treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company’s human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a branded Website, professional channels, and distributors; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 03/30/15
Founded in 2001

international stem cell corp (ISCO) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $246.1K
Chief Scientific Officer and Director
Total Annual Compensation: $196.9K
Compensation as of Fiscal Year 2014.

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Appoints Mahnaz Ebrahimi as Chief Financial Officer

On September 11, 2015, the Board of Directors of International Stem Cell Corporation appointed Mahnaz Ebrahimi, age 58, as its new Chief Financial Officer effective September 14, 2015. Ms. Ebrahimi has been assisting the company on accounting and SEC reporting matters as a consultant for the last several months. She has more than 25 years of experience in senior level financial management, accounting and SEC reporting matters, having worked with various publicly traded and privately held biotechnology, life science, and technology companies in an employee or a consultant capacity. Most recently, in addition to her consulting for the company, she has served as a consultant for Flux Power Holdings, assisting with the preparation of financial statements and periodic SEC reporting. Before that, she served as a consultant for Polaris Pharmaceuticals in 2014, where she was responsible for preparation of financial statements and for other accounting/finance activities, and Ocera Therapeutics in 2013, where she was heavily involved in and significantly contributed towards the successful completion of complex transactions.

International Stem Cell Corp. Updates on Next Phase of Research Collaboration with Rohto Pharmaceutical

International Stem Cell Corp. reported that it has entered into the second phase of the existing Research Agreement with Rohto Pharmaceutical Co. After successfully completing preliminary studies of ISCO's human parthenogenetic neural stem cells (hpNSCs) Rohto acknowledged that ISCO's proprietary cells demonstrate consistent high quality and are suitable for further use in Rohto's research. If Rohto successfully demonstrates hpNSCs' efficacy in rodent models, which could lead to a possible treatment of a variety of degenerative eye disorders, Rohto will enter into negotiations of a definitive license agreement with ISCO in order to license ISCO's proprietary technology for therapeutic and commercial use.

International Stem Cell Corporation will Change its Ticker to ISCO from ISCOD

Effective August 26, 2015, International Stem Cell Corporation will change its Pink Sheets LLC stock ticker symbol to ISCO from ISCOD.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $3.81 USD -0.05

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.12 USD +0.03
Bioheart Inc $0.0015 USD 0.0001
Cytori Therapeutics Inc $0.39 USD +0.022
Nuo Therapeutics Inc $0.08 USD +0.017
StemCells Inc $0.43 USD -0.0068
View Industry Companies

Industry Analysis


Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at